Currently predicting for Wed, 1 May 2024

Trading levels for KALV

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 11.70 3.11 %
R2 11.52 1.50 %
R1 11.41 0.500 %
Current price: 11.35
Support S1 11.04 -2.73 %
S2 10.93 -3.73 %
S3 10.74 -5.35 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 13.80 21.59 %
R2 12.58 10.84 %
R1 11.86 4.49 %
Current price 11.35
Support S1 11.21 -1.23%
S2 11.11 -2.11%
S3 11.04 -2.73%

KALV Predictions History

1 year ago
rajatrathee15.346367 predicted that KALV for 2022-10-05 is going

Rank:

3 years ago
Sander Levi Djupvik Strømberg predicted that KALV for 2021-04-16 is going $29.54 (20.82%)

Rank:

3 years ago
JS predicted that KALV for 2021-04-16 is going $25.64 (4.87%)

3 years ago
JS predicted that KALV for 2021-02-12 is going $36.47 (-14.33%)

3 years ago
Carrie Carrie predicted that KALV for 2021-02-12 is going

Rank:

3 years ago
Bashar Alshaar predicted that KALV for 2021-02-12 is going $44.00 (8.78%)

Rank:

3 years ago
JS predicted that KALV for 2021-02-11 is going $32.96 (-18.52%)

3 years ago
Bashar Alshaar predicted that KALV for 2021-02-11 is going $37.46 (-7.39%)

Rank:

3 years ago
JS predicted that KALV for 2020-10-20 is going $15.03 (-11.33%)

3 years ago
יונתן ברייטגנד predicted that KALV for 2020-10-20 is going $14.00 (-9.03%)

Rank:
Click to get the best stock tips daily for free!

About KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed ... KALV Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT